Showing results (1-10 of 46) with videos related to
Sort By:
Pageof 5
Autoimmunity Reviews|December 21, 2018
Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapiesLaurent Peyrin-Biroulet, Stephen Demarest, Ajay NirulaThe Journal of Experimental Medicine|June 21, 2006
Phosphoinositide-dependent kinase 1 targets protein kinase A in a pathway that regulates interleukin 4Ajay Nirula, Mary Ho, Hyewon Phee, et al.Current Opinion in Rheumatology|December 3, 2010
What is IgG4? A review of the biology of a unique immunoglobulin subtypeAjay Nirula, Scott M Glaser, Susan L Kalled, et al.Clinical Pharmacology and Therapeutics|October 23, 2021
A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab Into a First-in-Human Clinical TrialEmmanuel Chigutsa, Eric Jordie, Matthew Riggs, et al.Frontiers in Immunology|November 1, 2024
Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providersPaul Klekotka, Louis Lavoie, Beth Mitchell, et al.The Journal of Rheumatology|January 17, 2016
Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic ArthritisPhilip J Mease, Mark C Genovese, Alex Mutebi, et al.Journal of the American Academy of Dermatology|January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasisKim Papp, Alan Menter, Bruce Strober, et al.Journal of the American Academy of Dermatology|October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentKim Papp, Craig Leonardi, Alan Menter, et al.Infectious Diseases and Therapy|September 4, 2024
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19Dipak R Patel, Lisa Macpherson, Martin Bohm, et al.Chest|July 31, 2015
Biomarker Profiles in Asthma With High vs Low Airway Reversibility and Poor Disease ControlWilliam W Busse, Stephen T Holgate, Sally W Wenzel, et al.Pageof 5